# Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

> **NCT02934256** · PHASE2 · COMPLETED · sponsor: **Li Peng** · enrollment: 10 (actual)

## Conditions studied

- Vestibular Schwannoma
- Neurofibromatosis Type 2

## Interventions

- **DRUG:** Icotinib

## Key facts

- **NCT ID:** NCT02934256
- **Lead sponsor:** Li Peng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02934256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02934256, "Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02934256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*